{"acquisitions":[],"changes":[],"country":"SE","description":"Clinical-stage biotech developing BT-101, a mesenchymal stem-cell therapy for the genetic bone disease Osteogenesis Imperfecta. Targets children with brittle-bone disease who face frequent fractures and deformities. Two-year Phase 1/2 follow-up showed roughly 78% fewer fractures versus baseline, with origins in Karolinska Institutet research.","domain":"boostpharma.se","employees":null,"founded":2018,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":59.325117,"lng":18.071093,"location":"Stockholm, Sweden","multiples":[],"name":"Boost Pharma","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":3240000,"connectionsAmong":[],"currency":"EUR","date":"2025-11-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"boostpharma-se-2025-11-01-equity","source":{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-07","status":"attributed","url":null},"status":"attributed","type":"seed","url":null}],"slug":"boostpharma-se","sources":[{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-07","status":"attributed","url":null},{"fact":"existence","publisher":"boostpharma.se","retrievedAt":"2026-05-07","status":"self-reported","url":"https://boostpharma.se"},{"fact":"description","publisher":"boostpharma.se","retrievedAt":"2026-05-07","status":"self-reported","url":"https://boostpharma.se"}],"stage":"series-a","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":10800000,"traction":[],"updatedAt":"2026-05-07","valuations":[]}